Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...
How effective is Wegovy at treating MASH? Novo Nordisk announced the results of the ESSENCE phase 3 trial at the American ...
Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...
Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...
Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...
Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.
A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.
Weight-loss trends have been around for years, with the latest being GLP1 drugs like Ozempic or Wegovy. Meg Bowman, licensed nutritionist and trauma expert weighs in on what's causing these weight ...
There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.
The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...
Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.
After [losing out to Pfizer]( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback